Related Experiment Video

Updated: Jun 16, 2026

Antagonistic Effect of Jiawei Shengjiang San on a Rat Model of Diabetic Nephropathy: Related to EGFR/MAPK3/1 Signaling Pathway
08:15

Antagonistic Effect of Jiawei Shengjiang San on a Rat Model of Diabetic Nephropathy: Related to EGFR/MAPK3/1 Signaling Pathway

Published on: May 10, 2024

[Effects of angrographolide on plasma glucose level of experiment diabetic rats and its molecular mechanism]

Ping Yang1, Shen-Zhou Chen, Sheng-Jun Xiao

  • 1Department of pharmacology, Guilin Medical College, Guilin 541004, China. yp2805795@163.com

Zhong Yao Cai = Zhongyaocai = Journal of Chinese Medicinal Materials
|February 2, 2010
PubMed
Abstract

Insights

Angrographolide significantly reduces blood glucose in diabetic rats by protecting islet cells. This natural compound enhances antioxidant activity and may help manage diabetes through its anti-apoptotic effects.

Area of Science:

  • Pharmacology
  • Molecular Biology
  • Endocrinology

Context:

  • Diabetes mellitus is a complex metabolic disorder characterized by hyperglycemia.
  • Oxidative stress and islet cell apoptosis play crucial roles in the pathogenesis of diabetes.
  • Natural compounds are being explored for their therapeutic potential in managing diabetes.

Purpose:

  • To investigate the effects of angrographolide on plasma glucose levels in diabetic rats.
  • To elucidate the molecular mechanisms underlying angrographolide's action in diabetes.
  • To assess angrographolide's impact on oxidative stress markers and islet cell apoptosis.

Summary:

  • Diabetic rats treated with angrographolide showed significantly decreased plasma glucose levels and serum malondialdehyde (MDA) content.
  • Treatment with angrographolide led to increased serum insulin levels and superoxide dismutase (SOD) activity.
  • The expression of the anti-apoptotic gene Bcl-2 was upregulated in pancreatic cells of angrographolide-treated rats.

Impact:

  • Angrographolide demonstrates potential as a therapeutic agent for diabetes by inhibiting islet cell apoptosis.
  • The study suggests angrographolide's mechanism involves upregulating Bcl-2 expression and enhancing antioxidant defense.
  • These findings contribute to understanding natural product-based strategies for diabetes management.

More Related Videos

Retinal Pathophysiological Evaluation in a Rat Model09:11

Retinal Pathophysiological Evaluation in a Rat Model

Published on: May 6, 2022

Related Concept Videos

Oral Hypoglycemic Agents: Biguanides and Glitazones01:26

Oral Hypoglycemic Agents: Biguanides and Glitazones

Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood glucose levels...
Hormones Regulating Blood Glucose01:16

Hormones Regulating Blood Glucose

Insulin is released by beta cells of the pancreas when blood glucose levels are high. It facilitates glucose absorption and utilization in insulin-dependent cells with insulin receptors on their plasma membranes. Insulin promotes glucose uptake by increasing the number of glucose transport proteins in the cell membrane, allowing glucose to enter the cell. As a result, glucose utilization and ATP production are enhanced.
In addition to accelerating glucose uptake and utilization, insulin has...
Oral Hypoglycemic Agents: α-Glucosidase Inhibitors01:19

Oral Hypoglycemic Agents: α-Glucosidase Inhibitors

α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are typically...
Oral Hypoglycemic Agents: Glinides01:06

Oral Hypoglycemic Agents: Glinides

Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively manages...
Glucagon-like Receptor Agonists01:24

Glucagon-like Receptor Agonists

Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by the...
Dipeptidyl Peptidase 4 Inhibitors01:23

Dipeptidyl Peptidase 4 Inhibitors

Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a significant...